Quarterly report pursuant to Section 13 or 15(d)

Noncontrolling Interest

v3.21.1
Noncontrolling Interest
3 Months Ended
Mar. 31, 2021
Noncontrolling Interest [Abstract]  
Noncontrolling Interest

Note 10 — Noncontrolling Interest

 

The noncontrolling interest (“NCI”) included as a component of consolidated total stockholders’ equity is with respect to the Company’s majority-owned subsidiaries Lucid Diagnostics Inc. and Solys Diagnostics Inc., summarized for the periods indicated as follows:

 

    Three Months Ended
March 31, 2021
    Year Ended
December 31, 2020
 
NCI - equity (deficit) - beginning of period   $ (2,369 )   $ (814 )
Lucid Diagnostics Inc. 2018 Equity Plan stock option exercise           5  
Net loss attributable to NCI - Lucid Diagnostics Inc.     (663 )     (1,503 )
Net loss attributable to NCI - Solys Diagnostics Inc.     (16 )     (109 )
Stock-based compensation expense - Lucid Diagnostics Inc. 2018 Equity Plan     802       52  
NCI - equity (deficit) - end of period   $ (2,246 )   $ (2,369 )

 

Lucid Diagnostics Inc.

 

As of each of March 31, 2021, and December 31, 2020, there were 10,003,333 shares of common stock of Lucid Diagnostics Inc. issued and outstanding; of which PAVmed Inc. holds 8,187,499 shares, representing equity ownership interest of 81.85%, and PAVmed Inc. has a controlling financial interest, as of March 31, 2021 and December 31, 2020, respectively. Accordingly, Lucid Diagnostics Inc. is a consolidated majority-owned subsidiary of the Company, for which a provision of a noncontrolling interest (NCI) is included as a separate component of consolidated stockholders’ equity in the unaudited condensed consolidated balance sheet as of March 31, 2021 and December 31, 2020, along with the recognition of a net loss attributable to the NCI in the unaudited condensed consolidated statement of operations for the three months ended March 31, 2021 and 2020.

 

Solys Diagnostics Inc.

 

As of March 31, 2021 and December 31, 2020, there were 9,189,190 shares of common stock of Solys Diagnostics Inc. issued and outstanding, of which PAVmed Inc. holds a 90.3235% majority-interest ownership and has a controlling financial interest, with the remaining 9.6765% minority-interest ownership held by unrelated third parties. Accordingly, Solys Diagnostics Inc. is a consolidated majority-owned subsidiary of the Company, for which a provision of a noncontrolling interest (NCI) is included as a separate component of consolidated stockholders’ equity in the unaudited condensed consolidated balance sheet as of March 31, 2021 and December 31, 2020, along with the recognition of a net loss attributable to the NCI in the unaudited condensed consolidated statement of operations for the three months ended March 31, 2021 and 2020.